Elizabeth Olek

Elizabeth Olek, DO, MPH

Senior Vice President, Clinical Development

Dr. Elizabeth Olek, D.O, M.P.H., joined Kronos Bio in February 2022, and serves as Senior Vice President, Clinical Development, with primary responsibility for the strategic development and execution of the clinical trials that propel the company’s mission to bring life-changing therapies to patients.  Liz brings a wealth of expertise to the role, drawing on a distinguished career that has spanned the breadth of clinical development in the biotechnology industry.

Before joining Kronos Bio, her tenure at Loxo Oncology at Lilly was marked by her leadership in the clinical development of a hematology drug candidate and her significant contributions to the development and subsequent approval of selpercatinib, a targeted therapy for thyroid and lung cancer.  Prior to this, at Puma Biotechnology, Liz led a pivotal clinical program in breast cancer, honing her leadership in oncology drug development.

Liz’s strategic consulting for early-stage biotech firms such as Lumena Pharmaceuticals, aTyr Pharma, and Receptos showcased her ability to guide key clinical programs from conception to fruition.  Her earlier roles as Chief Medical Officer as Achillion Pharmaceuticals and in various leadership positions at Novartis provided her with a deep understanding of the biotechnology landscape and the complexities of bringing innovative therapies to market.  Liz began her career in industry at Genetics Institute and Intermune.

Liz received a Bachelor of Pharmacy degree from the University of the Sciences in Philadelphia, a Doctor of Osteopathy from the Philadelphia College of Osteopathic Medicine, and a Master of Public Health from the Boston University School of Public Health.  Additionally, her training in infectious diseases at Boston Medical Center and Finland Laboratory, coupled with years in HIV/ID practice, have endowed her with a patient-centric perspective that is invaluable in her role at Kronos Bio.  As our SVP, Clinical Development, Liz leverages her comprehensive clinical and pharmaceutical expertise to ensure that Kronos Bio’s clinical trials are not only scientifically rigorous, but also strategically poised to meet pressing needs in patient treatment, thereby delivering on the company’s mission to bring life-changing therapies to market.